Liquid Suspension Trends In The CDMO Space

Liquid suspension formulations are emerging as a major growth area in the pharmaceutical industry, fueled by rising demand for patient‑friendly dosage forms and advancements in formulation technology. As CDMOs take on a larger role in supporting complex drug delivery systems, liquid suspensions have become a key focus due to their dosing flexibility, ease of swallowing, and suitability for pediatric and geriatric populations. Market projections reflect this momentum, with global non‑sterile liquid and suspension products expected to grow from USD 2.6 billion in 2022 to USD 5.2 billion by 2033.

Innovations such as nanotechnology‑enhanced bioavailability, taste‑masking systems, and extended‑release suspension platforms continue to expand the therapeutic potential of these formulations. However, challenges, including stability, particle size control, and stringent regulatory requirements, demand specialized expertise and robust manufacturing infrastructure.

CDMOs play a critical role by offering advanced formulation capabilities, scalable production, and deep regulatory knowledge. Mikart has strengthened its leadership in this area by expanding liquid suspension production capacity, adding nitrogen blanketing capabilities to support stability, and leveraging state‑of‑the‑art technologies to improve efficiency and quality.

As the shift toward patient‑centric therapies accelerates, liquid suspensions will continue to shape the future of drug development, with CDMOs like Mikart at the forefront of innovation.